Ir-6: A Novel Iridium (III) Organometallic Derivative for Inhibition of Human Platelet Activation

Clicks: 293
ID: 12202
2018
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Steady

Ranked #31 of 89 articles by views in bioinorganic chemistry and applications

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Abstract
Platelet activation has been reported to play a major role in arterial thrombosis, cancer metastasis, and progression. Recently, we developed a novel Ir(III)-based compound, [Ir(Cp)1-(2-pyridyl)-3-(4-dimethylaminophenyl)imidazo[1,5-a]pyridine Cl]BF4 or Ir-6 and assessed its effectiveness as an antiplatelet drug. Ir-6 exhibited higher potency against human platelet aggregation stimulated by collagen. Ir-6 also inhibited ATP-release, intracellular Ca2
Reference Key
renshi2018ir6bioinorganic Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Shyu, Ren-Shi;Khamrang, Themmila;Sheu, Joen-Rong;Hsia, Chih-Wei;Velusamy, Marappan;Hsia, Chih-Hsuan;Chou, Duen-Suey;Chang, Chao-Chien;Shyu, Ren-Shi;Khamrang, Themmila;Sheu, Joen-Rong;Hsia, Chih-Wei;Velusamy, Marappan;Hsia, Chih-Hsuan;Chou, Duen-Suey;Chang, Chao-Chien;
Journal bioinorganic chemistry and applications
Year 2018
DOI
10.1155/2018/8291393
URL
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

No comments yet. Be the first to comment on this article.